• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Aryl Ether-Derived Sphingosine-1-Phosphate Receptor (S1P) Modulators: Optimization of the PK, PD, and Safety Profiles.芳基醚衍生的1-磷酸鞘氨醇受体（S1P）调节剂：药代动力学、药效学和安全性的优化
ACS Med Chem Lett. 2020 Aug 11;11(9):1766-1772. doi: 10.1021/acsmedchemlett.0c00333. eCollection 2020 Sep 10.
2
Bicyclic Ligand-Biased Agonists of S1P: Exploring Side Chain Modifications to Modulate the PK, PD, and Safety Profiles.双环配体偏向性 S1P 激动剂：探索侧链修饰以调节 PK、PD 和安全性特征。
J Med Chem. 2021 Feb 11;64(3):1454-1480. doi: 10.1021/acs.jmedchem.0c01109. Epub 2021 Jan 25.
3
Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P) Modulator Advanced into Clinical Trials.（1R,3S)-1-氨基-3-((S)-6-(2-甲氧基苯乙基)-5,6,7,8-四氢萘-2-基)环戊基)甲醇（BMS-986166）的鉴定和临床前药理学：一种进入临床试验的分化型鞘氨醇-1-磷酸受体 1（S1P）调节剂。
J Med Chem. 2019 Mar 14;62(5):2265-2285. doi: 10.1021/acs.jmedchem.8b01695. Epub 2019 Mar 6.
4
Identification of potent tricyclic prodrug S1P receptor modulators.强效三环前药鞘氨醇-1-磷酸（S1P）受体调节剂的鉴定
Medchemcomm. 2016 Nov 25;8(4):725-729. doi: 10.1039/c6md00539j. eCollection 2017 Apr 1.
5
Identification and Structure-Activity Relationship (SAR) of potent and selective oxadiazole-based agonists of sphingosine-1-phosphate receptor (S1P).鉴定和基于结构活性关系（SAR）的新型强效和选择性的基于恶二唑的 Sphingosine-1-Phosphate Receptor（S1P）激动剂。
Bioorg Chem. 2019 Feb;82:41-57. doi: 10.1016/j.bioorg.2018.09.008. Epub 2018 Sep 11.
6
S1P Modulator-Induced G Signaling and -Arrestin Recruitment Are Both Necessary to Induce Rapid and Efficient Reduction of Blood Lymphocyte Count In Vivo.鞘氨醇 1 磷酸调节剂诱导的 G 蛋白信号转导和 - 抑制蛋白募集对于体内快速有效的降低血液淋巴细胞计数都是必需的。
Mol Pharmacol. 2018 Feb;93(2):109-118. doi: 10.1124/mol.117.109140. Epub 2017 Dec 4.
7
Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators.鞘氨醇-1-磷酸受体调节剂的临床药理学、疗效及安全性方面
Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):879-95. doi: 10.1080/17425255.2016.1196188. Epub 2016 Jun 13.
8
Docking Studies of Fingolimod and S1P Agonists.芬戈莫德与S1P激动剂的对接研究。
Front Pharmacol. 2020 Mar 10;11:247. doi: 10.3389/fphar.2020.00247. eCollection 2020.
9
Development of a selective S1P1 receptor agonist, Syl930, as a potential therapeutic agent for autoimmune encephalitis.开发一种选择性 S1P1 受体激动剂 Syl930，作为自身免疫性脑炎的潜在治疗药物。
Biochem Pharmacol. 2014 Jul 1;90(1):50-61. doi: 10.1016/j.bcp.2014.04.010. Epub 2014 Apr 26.
10
Cenerimod, a novel selective S1P receptor modulator with unique signaling properties.西尼莫德，一种新型选择性 S1P 受体调节剂，具有独特的信号传导特性。
Pharmacol Res Perspect. 2017 Dec;5(6). doi: 10.1002/prp2.370.

引用本文的文献

1
Multicomponent Synthesis of α-Branched Amines via a Zinc-Mediated Carbonyl Alkylative Amination Reaction.通过锌介导的羰基烷基化胺化反应多组分合成α-支链胺
J Am Chem Soc. 2024 Apr 3;146(13):9045-9062. doi: 10.1021/jacs.3c14037. Epub 2024 Mar 15.

本文引用的文献

1
The safety and pharmacokinetics of a novel, selective S1P1R modulator in healthy participants.新型、选择性 S1P1R 调节剂在健康受试者中的安全性和药代动力学。
Expert Opin Investig Drugs. 2020 Apr;29(4):411-422. doi: 10.1080/13543784.2020.1742322.
2
Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P) Modulator Advanced into Clinical Trials.（1R,3S)-1-氨基-3-((S)-6-(2-甲氧基苯乙基)-5,6,7,8-四氢萘-2-基)环戊基)甲醇（BMS-986166）的鉴定和临床前药理学：一种进入临床试验的分化型鞘氨醇-1-磷酸受体 1（S1P）调节剂。
J Med Chem. 2019 Mar 14;62(5):2265-2285. doi: 10.1021/acs.jmedchem.8b01695. Epub 2019 Mar 6.
3
Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases.针对 S1P 受体信号通路作为治疗自身免疫和炎症性疾病的有前途的方法。
Pharmacol Res. 2020 Apr;154:104170. doi: 10.1016/j.phrs.2019.02.009. Epub 2019 Feb 15.
4
Expanding Role of T Cells in Human Autoimmune Diseases of the Central Nervous System.T细胞在人类中枢神经系统自身免疫性疾病中不断扩大的作用。
Front Immunol. 2017 Jun 7;8:652. doi: 10.3389/fimmu.2017.00652. eCollection 2017.
5
Modulators of Sphingosine-1-phosphate Pathway Biology: Recent Advances of Sphingosine-1-phosphate Receptor 1 (S1P) Agonists and Future Perspectives.鞘氨醇-1-磷酸途径生物学的调节剂：鞘氨醇-1-磷酸受体1（S1P）激动剂的最新进展及未来展望
J Med Chem. 2017 Jul 13;60(13):5267-5289. doi: 10.1021/acs.jmedchem.6b01575. Epub 2017 Mar 30.
6
Asymmetric Hydroboration Approach to the Scalable Synthesis of ((1R,3S)-1-Amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986104) as a Potent S1P Receptor Modulator.通过不对称硼氢化反应可扩展合成((1R,3S)-1-氨基-3-((R)-6-己基-5,6,7,8-四氢萘-2-基)环戊基)甲醇（BMS-986104）作为一种强效的鞘氨醇-1-磷酸受体调节剂 。
J Med Chem. 2016 Dec 22;59(24):11138-11147. doi: 10.1021/acs.jmedchem.6b01433. Epub 2016 Dec 7.
7
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.BMS-986104的鉴定与临床前药理学：一种用于临床试验的差异化S1P1受体调节剂
ACS Med Chem Lett. 2016 Jan 19;7(3):283-8. doi: 10.1021/acsmedchemlett.5b00448. eCollection 2016 Mar 10.
8
Sphingosine 1-phosphate receptor 1 agonists: a patent review (2013-2015).鞘氨醇 1-磷酸受体 1 激动剂：专利审查（2013-2015）。
Expert Opin Ther Pat. 2016;26(4):455-70. doi: 10.1517/13543776.2016.1157165. Epub 2016 Mar 15.
9
Sphingosine 1-phosphate receptor modulators in multiple sclerosis.鞘氨醇-1-磷酸受体调节剂在多发性硬化症中的应用
CNS Drugs. 2015 Jul;29(7):565-75. doi: 10.1007/s40263-015-0261-z.
10
S1P signaling: new therapies and opportunities.鞘氨醇-1-磷酸信号传导：新疗法与机遇
F1000Prime Rep. 2014 Dec 1;6:109. doi: 10.12703/P6-109. eCollection 2014.

芳基醚衍生的1-磷酸鞘氨醇受体（S1P）调节剂：药代动力学、药效学和安全性的优化

Aryl Ether-Derived Sphingosine-1-Phosphate Receptor (S1P) Modulators: Optimization of the PK, PD, and Safety Profiles.

作者信息

Xiao Zili, Yang Michael G, Dhar T G Murali, Xiao Hai-Yun, Gilmore John L, Marcoux David, McIntyre Kim W, Taylor Tracy L, Shi Hong, Levesque Paul C, Marino Anthony M, Cornelius Georgia, Mathur Arvind, Shen Ding Ren, Cvijic Mary Ellen, Lehman-McKeeman Lois D, Sun Huadong, Xie Jenny H, Carter Percy H, Dyckman Alaric J

机构信息

Research and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.

出版信息

ACS Med Chem Lett. 2020 Aug 11;11(9):1766-1772. doi: 10.1021/acsmedchemlett.0c00333. eCollection 2020 Sep 10.

DOI:10.1021/acsmedchemlett.0c00333
PMID:32944145
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7488280/
Abstract

Efforts aimed at increasing the in vivo potency and reducing the elimination half-life of and led to the identification of aryl ether and thioether-derived bicyclic S1P differentiated modulators -. The effects of analogs - on lymphocyte reduction in the rat (desired pharmacology) along with pulmonary- and cardiovascular-related effects (undesired pharmacology) are described. Optimization of the overall properties in the aryl ether series yielded , and the predicted margin of safety against the cardiovascular effects of would be large enough for human studies. Importantly, compared to and , compound had a better profile in both potency (ED < 0.05 mg/kg) and predicted human half-life ( ∼ 5 days).

摘要

旨在提高体内效力并缩短[具体药物1]和[具体药物2]消除半衰期的研究工作，促成了芳基醚和硫醚衍生的双环S1P差异化调节剂[具体化合物1]-[具体化合物2]的发现。描述了类似物[具体化合物1]-[具体化合物2]对大鼠淋巴细胞减少（预期药理学作用）以及与肺和心血管相关的作用（非预期药理学作用）。芳基醚系列整体性质的优化产生了[具体化合物3]，并且针对[具体化合物3]心血管作用的预测安全边际对于人体研究而言足够大。重要的是，与[具体化合物1]和[具体化合物2]相比，化合物[具体化合物3]在效力（ED<0.05mg/kg）和预测的人体半衰期（约5天）方面均具有更好的特性。